CymaBay Therapeutics, Inc. — Net Income by Fiscal Year
12 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/13f7a586-1ef9-4cd4-9db1-a5957ab675f3/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2023 | $-105.4M | 2023-01-01 – 2023-12-31 | evidence 0001193125-24-050758 |
| FY 2022 | $-106.0M | 2022-01-01 – 2022-12-31 | evidence 0001193125-23-077859 |
| FY 2021 | $-90.0M | 2021-01-01 – 2021-12-31 | evidence 0001193125-22-078287 |
| FY 2020 | $-51.0M | 2020-01-01 – 2020-12-31 | evidence 0001193125-21-094424 |
| FY 2019 | $-102.8M | 2019-01-01 – 2019-12-31 | evidence 0001193125-20-074946 |
| FY 2018 | $-72.5M | 2018-01-01 – 2018-12-31 | evidence 0001564590-19-005435 |
| FY 2017 | $-27.6M | 2017-01-01 – 2017-12-31 | evidence 0001564590-18-005831 |
| FY 2016 | $-26.7M | 2016-01-01 – 2016-12-31 | evidence 0001193125-17-093759 |
| FY 2015 | $-15.5M | 2015-01-01 – 2015-12-31 | evidence 0001193125-16-521392 |
| FY 2014 | $-31.9M | 2014-01-01 – 2014-12-31 | evidence 0001193125-15-101933 |
| FY 2013 | $-10.1M | 2013-01-01 – 2013-12-31 | evidence 0001193125-14-124127 |
| FY 2012 | $-11.3M | 2012-01-01 – 2012-12-31 | evidence 0001193125-14-124127 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
CymaBay Therapeutics, Inc. — all facts · Revenue · Operating Income